Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H23N5O5 |
Molecular Weight | 389.4057 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(N(CCCNCC(O)C3=CC(O)=CC(O)=C3)C=N2)C(=O)N(C)C1=O
InChI
InChIKey=WVLAAKXASPCBGT-UHFFFAOYSA-N
InChI=1S/C18H23N5O5/c1-21-16-15(17(27)22(2)18(21)28)23(10-20-16)5-3-4-19-9-14(26)11-6-12(24)8-13(25)7-11/h6-8,10,14,19,24-26H,3-5,9H2,1-2H3
Reproterol is a short-acting β2 adrenoreceptor agonist used in the treatment of asthma. Reproterol increases the generation of cAMP in isolated peripheral blood monocytes in vitro more effectively than does orciprenaline. In the presence of the highly potent but nonselective ß-antagonist, propranolol, the cAMP-generating action of reproterol was inhibited only partially. Reproterol has gained wide use when it was licensed as a fixed combination therapy with cromoglycate. Until today, the bronchodilator effects of reproterol and the bronchoprotective and anti-inflammatory actions of cromoglycate combined in one inhaler remain the successful fixed combination of a disease-modifying and symptomatic drug for the treatment of asthma.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Phosphodiesterase, mouse Sources: https://www.ncbi.nlm.nih.gov/pubmed/15219266 |
52.0 µM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Screening of beta-2 agonists and confirmation of fenoterol, orciprenaline, reproterol and terbutaline with gas chromatography-mass spectrometry as tetrahydroisoquinoline derivatives. | 2001 Feb 10 |
|
[Exercise-induced asthma. The spray belongs in the "athletic shoe"]. | 2001 Jul 19 |
|
Conductimetric determination of reproterol HCl and pipazethate HCl and salbutamol sulphate in their pharmaceutical formulations. | 2001 Oct |
|
[With the correct training conditions and appropriate prophylaxis. To make asthma patients fit for sports]. | 2003 Apr 10 |
|
Mononuclear cell membranes: stabilization by reproterol and cromoglycate, destabilization by fenoterol and salbutamol. | 2006 |
|
Prevention of exercise-induced asthma by a fixed combination of disodium cromoglycate plus reproterol compared with montelukast in young patients. | 2008 |
|
Exercise-induced asthma: critical analysis of the protective role of montelukast. | 2009 Oct 22 |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03CC14
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
||
|
WHO-VATC |
QR03CC14
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
||
|
WHO-ATC |
R03AC15
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
||
|
WHO-VATC |
QR03AK05
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
||
|
WHO-ATC |
R03AK05
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
||
|
WHO-VATC |
QR03AC15
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10283MIG
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
REPROTEROL
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
25654
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
DB12846
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
C014792
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
258-956-1
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
C152194
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
11941YC6RN
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
m9529
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1095607
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
35373
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | RxNorm | ||
|
54063-54-6
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
100000080550
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
DTXSID8023553
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
2368
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY | |||
|
3501
Created by
admin on Fri Dec 15 18:48:38 GMT 2023 , Edited by admin on Fri Dec 15 18:48:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)